397 related articles for article (PubMed ID: 18973234)
21. [Bone marrow stem cells transplantation improve locomotive function of dystrophin/utrophin gene double knock-out mice].
Zhang C; Chen SL; Liu XR; Huang W; Zhang WX; Lu XL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):160-3. PubMed ID: 12905711
[TBL] [Abstract][Full Text] [Related]
22. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
[TBL] [Abstract][Full Text] [Related]
23. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins.
Tidball JG; Wehling-Henricks M
Mol Genet Metab; 2004 Aug; 82(4):312-20. PubMed ID: 15308129
[TBL] [Abstract][Full Text] [Related]
24. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy.
Guo C; Willem M; Werner A; Raivich G; Emerson M; Neyses L; Mayer U
Hum Mol Genet; 2006 Mar; 15(6):989-98. PubMed ID: 16476707
[TBL] [Abstract][Full Text] [Related]
25. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
[TBL] [Abstract][Full Text] [Related]
26. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy.
Berry SE; Liu J; Chaney EJ; Kaufman SJ
Regen Med; 2007 May; 2(3):275-88. PubMed ID: 17511564
[TBL] [Abstract][Full Text] [Related]
27. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
Athanasopoulos T; Foster H; Foster K; Dickson G
Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
[TBL] [Abstract][Full Text] [Related]
28. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
29. [Utrophin, a way to cure Duchenne muscle dystrophy].
Gillis JM
Med Sci (Paris); 2004 Apr; 20(4):442-7. PubMed ID: 15124117
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers.
Miyazaki D; Nakamura A; Fukushima K; Yoshida K; Takeda S; Ikeda S
Hum Mol Genet; 2011 May; 20(9):1787-99. PubMed ID: 21320869
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
[TBL] [Abstract][Full Text] [Related]
32. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy.
Bia BL; Cassidy PJ; Young ME; Rafael JA; Leighton B; Davies KE; Radda GK; Clarke K
J Mol Cell Cardiol; 1999 Oct; 31(10):1857-62. PubMed ID: 10525423
[TBL] [Abstract][Full Text] [Related]
33. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy.
Chaubourt E; Fossier P; Baux G; Leprince C; Israël M; De La Porte S
Neurobiol Dis; 1999 Dec; 6(6):499-507. PubMed ID: 10600405
[TBL] [Abstract][Full Text] [Related]
34. Downstream utrophin enhancer is required for expression of utrophin in skeletal muscle.
Tanihata J; Suzuki N; Miyagoe-Suzuki Y; Imaizumi K; Takeda S
J Gene Med; 2008 Jun; 10(6):702-13. PubMed ID: 18338831
[TBL] [Abstract][Full Text] [Related]
35. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura P; Jasmin BJ
Trends Mol Med; 2006 Mar; 12(3):122-9. PubMed ID: 16443393
[TBL] [Abstract][Full Text] [Related]
36. [Development of new therapy on muscular dystrophy].
Takeda S
Rinsho Shinkeigaku; 2001 Dec; 41(12):1154-6. PubMed ID: 12235824
[TBL] [Abstract][Full Text] [Related]
37. Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice.
Kawano R; Ishizaki M; Maeda Y; Uchida Y; Kimura E; Uchino M
Mol Ther; 2008 May; 16(5):825-31. PubMed ID: 18334987
[TBL] [Abstract][Full Text] [Related]
38. Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice.
Heller KN; Montgomery CL; Shontz KM; Clark KR; Mendell JR; Rodino-Klapac LR
Hum Gene Ther; 2015 Oct; 26(10):647-56. PubMed ID: 26076707
[TBL] [Abstract][Full Text] [Related]
39. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
[TBL] [Abstract][Full Text] [Related]
40. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
Ferrer A; Wells KE; Wells DJ
Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
